Nestin expression throughout multistep pathogenesis of multiple myeloma
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24329895
DOI
10.1111/bjh.12689
Knihovny.cz E-resources
- Keywords
- flow cytometry, monoclonal gammopathy, multiple myeloma, nestin, stem cells,
- MeSH
- Adult MeSH
- Immunophenotyping MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger genetics MeSH
- Multiple Myeloma diagnosis immunology metabolism pathology MeSH
- Monoclonal Gammopathy of Undetermined Significance metabolism MeSH
- Biomarkers, Tumor biosynthesis genetics MeSH
- Tumor Cells, Cultured MeSH
- Neoplasm Proteins biosynthesis genetics MeSH
- Nestin biosynthesis genetics MeSH
- Leukemia, Plasma Cell metabolism MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Recurrence MeSH
- RNA, Neoplasm genetics MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- RNA, Messenger MeSH
- Biomarkers, Tumor MeSH
- Neoplasm Proteins MeSH
- Nestin MeSH
- RNA, Neoplasm MeSH
The stem cell marker nestin (NES) is found in dividing cells of developing and regenerating tissues. Upon terminal differentiation, NES expression is diminished but may be re-expressed following injury or in cancer. Surprisingly, we recently confirmed NES as a tumour-specific marker for mature CD138(+) 38(+) plasma cells (PC) in multiple myeloma (MM). The present study analysed NES expression throughout the spectrum of MM developmental stages, starting with individuals with no haematological malignancy, through monoclonal gammopathy of undetermined significance (MGUS) and MM to plasma cell leukaemia (PCL) and MM cell lines. NES was analysed in bone marrow PC of 163 MM, four PCL and nine MGUS patients, 10 individuals with no haematological malignancy and 6 myeloma cell lines (OPM-2, RPMI-8226, MOLP-8, U-266, EJM, NCI-H929) by flow cytometry and/or real-time polymerase chain reaction or immunochemistry. We observed a tendency of increased NES expression in parallel with disease progression. NES was evaluated as a reliable marker for accurate discrimination between MM patients and the control group. High NES levels were strongly associated with the presence of 1q21 gain. For the first time, NES was demonstrated to predict worse response to conventional therapy/novel agents. These results suggest that NES might become a useful clinical parameter with an important role in MM pathogenesis.
References provided by Crossref.org
Nestin as a marker of cancer stem cells
